Drugs / CPI-200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03953742 | Jul 2019 → Feb 2022 | — | Coordination Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPI-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03953742 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT03953742 ↗ |